Therefore, our aim was to verify the preliminary hypothesis that both IL-33 and IL-13 are higher in patients with diffuse SSc and interstitial lung disease (SSc-ILD) compared both to SSc patients without ILD, as measured through pulmonary function tests (DLco, TLC, FVC), and to healthy controls. This evidence concerns the gene IL33 and systemic sclerosis.